EIDX News and Press, Eidos Therapeutics Inc. From 12/14/20

A bout of dealmaking began over the weekend as AstraZeneca bulked up its rare disease portfolio with the $39B purchase of Alexion Pharmaceuticals (its biggest acquisition on record).Elsewhere in the pharma sector, GlaxoSmithKline (GSK) was reported to be in the race to buy Eidos Therapeutics ...

WeissLaw LLP Reminds EIDX, IPHI, TGC, and APXT Shareholders About Its Ongoing Investigations NEW YORK , Dec. 11, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any que...

Merger activity increased last week with five new deals announced. The merger of IHS Markit and S&P Global for $44 billion. The acquisition of Slack Technologies by salesforce.com. For further details see: Merger Arbitrage Mondays: Yet Another Deal Receives A Higher ...

WeissLaw LLP Reminds IPHI, EMIS, and EIDX Shareholders About Its Ongoing Investigations NEW YORK , Dec. 4, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions...

Merger activity decreased last week with one new deal announced. The acquisition of The Goldfield Corporation (GV) by an affiliate of First Reserve. Front Yard Residential Corporation (RESI) and Pretium and Ares Management Corporation (ARES) amend their merger agreement. For...

WeissLaw LLP Reminds PTI, MVC, and EIDX Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, Nov. 23, 2020 NEW YORK , Nov. 23, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to d...

Merger activity remained steady last week with four new deals announced. The acquisition of Endurance International Group Holdings by Clearlake Capital Group. The acquisition of Navistar International Corporation by TRATON SE. For further details see: Merger Ar...

- Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio’s clinical and commercial development infrastructure to bear upon Eidos’ Acoramidis - New Drug Application f or Fosdenopterin f or t he ...

Eidos Therapeutics (EIDX): Q3 GAAP EPS of -$0.79 misses by $0.12.Revenue of $0.13M (-99.5% Y/Y)Cash and cash equivalents of $147.3M.Press Release For further details see: Eidos Therapeutics EPS misses by $0.12

SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company’s operations. “The completion of enrollment in our P...